

October 29, 2026

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
--	--

Dear Sir / Madam,

Sub: Outcome of the Board Meeting – October 29, 2026

We would like to inform that the Board of Directors of the Company at their meeting held on October 29, 2026, has *inter alia* transacted and approved the following businesses:

(1) Approval of Unaudited Financial Results for the quarter and half-year ended September 30, 2026

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, which are **annexed** herewith along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company.

The financial results will be available on the website of the Company at www.lauruslabs.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com, respectively.

(2) Approval for the payment of Interim Dividend for FY 2026-27

The Board of Directors approved the payment of Interim Dividend of Re. 1.00/- (i.e., 50%) per equity share of Rs.2/- each, for the Financial Year 2026-27.

Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed “November 6, 2026” as the “Record Date” for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 19, 2026.

(3) Approval for the appointment of Mr. Kundan Kumar Jha, as Joint Company Secretary

The Board of Directors approved the appointment of Mr. Kundan Kumar Jha (Associate Member of the Institute of Company Secretaries of India holding Membership No. A17612), as Joint Company Secretary, being a Key Managerial Personnel of the Company, with effect from November 1, 2026, in line with the Company’s succession planning process.

The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST).

This is for your information and records.

Thanking you.

Yours sincerely,

For **Laurus Labs Limited**

VANTARAM

VENKATA RAVI
KUMAR

Digitally signed by VANTARAM
VENKATA RAVI KUMAR
Date: 2026.10.29 14:31:20 +05'30'

V V Ravi Kumar

Executive Director and CFO

DIN: 01424180

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

LAURUS LABS LIMITED
(CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021
Corp. Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India.

Tel: +91 040 6659 4333 ; Fax : +91 040 6659 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

₹ in Crores

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations	2,206.37	2,026.31	1,653.47	4,232.68	3,223.04	6,812.90
	(b) Other income	13.01	9.18	26.96	22.19	37.39	54.95
	Total income	2,219.38	2,035.49	1,680.43	4,254.87	3,260.43	6,867.85
2	Expenses						
	(a) Cost of materials consumed	900.69	785.77	676.75	1,686.46	1,276.16	2,794.34
	(b) Purchase of traded goods	45.01	35.12	30.70	80.13	69.20	172.56
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(129.61)	(64.88)	(44.01)	(194.49)	(44.57)	(271.44)
	(d) Employee benefits expense	265.71	258.70	215.56	524.41	430.36	895.45
	(e) Other expenses	374.27	373.33	371.21	747.60	706.50	1,444.28
	(f) Depreciation and amortisation expense	127.39	123.87	120.49	251.26	237.33	480.05
	(g) Finance costs	44.10	42.22	40.00	86.32	91.50	170.73
	Total expenses	1,627.56	1,554.13	1,410.70	3,181.69	2,766.48	5,685.97
3	Profit before tax (1-2)	591.82	481.36	269.73	1,073.18	493.95	1,181.88
4	Tax expense						
	(a) Current tax	162.94	134.88	87.91	297.82	147.93	297.52
	(b) Deferred tax	(7.86)	(15.51)	(11.93)	(23.37)	(8.81)	(5.49)
	Total Tax expense	155.08	119.37	75.98	274.45	139.12	292.03
5	Net Profit after tax (3-4)	436.74	361.99	193.75	798.73	354.83	889.85
6	Share of net profit/(loss) from associates and joint venture, net of tax	(0.55)	0.08	0.74	(0.47)	1.34	0.29
7	Net Profit after taxes and share of net profit/(loss) from associates and joint venture (5+6)	436.19	362.07	194.49	798.26	356.17	890.14
8	Other comprehensive income/(loss)						
(a)	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/ (losses) on defined benefit plans	(2.42)	(2.42)	(0.26)	(4.84)	(0.51)	3.64
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	0.61	0.61	0.07	1.22	0.13	(0.91)
	(iii) Share in Other comprehensive income of associates and joint venture, net of tax	(0.01)	-	(0.01)	(0.01)	(0.01)	0.11
(b)	Items that will be reclassified subsequently to profit or loss:						
	Exchange differences on translating the financial statements of foreign operations	(0.52)	(0.40)	(5.47)	(0.92)	(5.99)	(8.74)
	Total other comprehensive income/(loss), net of tax	(2.34)	(2.21)	(5.67)	(4.55)	(6.38)	(5.90)
9	Total comprehensive income (7+8)	433.85	359.86	188.82	793.71	349.79	884.24
10	Profit for the period attributable to:						
	i) Equity holders of the company	441.48	367.60	194.97	809.08	357.99	888.79
	ii) Non-controlling interests	(5.29)	(5.53)	(0.48)	(10.82)	(1.82)	1.35
11	Total comprehensive income for the period attributable to:						
	i) Equity holders of the company	439.14	365.39	189.30	804.53	351.61	882.90
	ii) Non-controlling interests	(5.29)	(5.53)	(0.48)	(10.82)	(1.82)	1.34
12	Paid-up equity share capital (face value ₹ 2/- each)	108.06	108.05	107.96	108.06	107.96	107.97
13	Other equity						5,192.09
14	Earnings per equity share (face value ₹ 2/- each)						
	- Basic (₹)	8.17	6.81	3.61	14.98	6.63	16.47
	- Diluted (₹)	8.16	6.80	3.61	14.96	6.63	16.45
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

See accompanying notes to the financial results



Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Sl. No.	Particulars	As at September 30, 2026	As at March 31, 2026
		Unaudited	Audited
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	3,846.55	3,873.23
(b)	Right-of-use assets	241.30	232.71
(c)	Capital work-in- progress	1,282.44	773.28
(d)	Goodwill	246.30	246.30
(e)	Other intangible assets	17.20	18.40
(f)	Financial assets		
(i)	Investments	310.02	309.27
(ii)	Other financial assets	46.38	44.26
(g)	Deferred tax assets (net)	19.74	-
(h)	Income tax assets (net)	4.54	2.44
(i)	Other non-current assets	315.64	182.09
	Total non-current assets (1)	6,330.11	5,681.98
	Current assets		
(a)	Inventories	2,659.06	2,342.16
(b)	Financial assets		
(i)	Trade receivables	2,241.53	2,155.04
(ii)	Cash and cash equivalents	24.45	112.66
(iii)	Bank balances other than Cash and cash equivalents	4.29	1.04
(iv)	Loans	0.95	0.93
(v)	Other financial assets	4.63	3.21
(c)	Other current assets	248.66	214.17
	Total current assets (2)	5,183.57	4,829.21
	Total - assets (1+2)	11,513.68	10,511.19
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	108.06	107.97
(b)	Other equity	5,952.51	5,192.09
	Total equity attributable to equity holders of Holding Company	6,060.57	5,300.06
(c)	Non-controlling interests	120.48	131.30
	Total equity (1)	6,181.05	5,431.36
	Non-current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	553.32	611.34
(ii)	Lease liabilities	127.59	111.49
(iii)	Other financial liabilities	25.24	20.63
(b)	Provisions	145.01	132.09
(c)	Deferred tax liability (net)	26.23	29.38
(d)	Other non-current liabilities	501.15	539.47
	Total non-current liabilities (2)	1,378.54	1,444.40
	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	1,936.56	1,786.15
(ii)	Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	42.44	51.20
	-total outstanding dues of creditors other than micro enterprises and small enterprises	1,258.93	1,200.89
(iii)	Lease liabilities	7.66	9.50
(iv)	Other financial liabilities	335.54	333.58
(b)	Other current liabilities	159.72	161.95
(c)	Provisions	42.84	37.89
(d)	Income tax liabilities (net)	170.40	54.27
	Total current liabilities (3)	3,954.09	3,635.43
	Total - equity and liabilities (1+2+3)	11,513.68	10,511.19



Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com


Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518



Consolidated Statement of Cash Flows

₹ in Crores

Particulars	For the six months ended September 30, 2026	For the six months ended September 30, 2025
	Unaudited	Unaudited
Cash flow from operating activities		
Profit before tax	1,073.18	493.95
Adjustments for :		
Depreciation and amortisation	251.26	237.33
(Profit)/Loss on sale of property, plant and equipment (net)	0.42	4.41
Interest income	(4.60)	(4.83)
Interest expenses	81.98	88.66
Share based payment expense	5.47	5.41
Net gain on foreign exchange fluctuations (unrealised)	(8.67)	(19.26)
Allowance for expected credit loss and bad debts (net)	38.06	52.09
Operating profit before working capital changes	1,437.10	857.76
Movement In working capital:		
Increase in inventories	(316.91)	(86.02)
(Increase)/Decrease in trade receivables	(151.21)	124.74
Increase in financial and non-financial assets	(26.34)	(22.05)
Increase in trade payables	64.16	59.14
Increase/ (Decrease) in financial, non-financial liabilities and provisions	(19.74)	253.81
Cash generated from operations	987.06	1,187.38
Income tax paid	(182.10)	(94.25)
Net cash generated from operating activities (A)	804.96	1,093.13
Cash flow from investing activities		
Purchase of property, plant and equipment, including intangible assets, and movement in capital work in progress, capital advances and capital creditors	(864.19)	(488.91)
Proceeds from sale of property, plant and equipment	0.95	2.97
Movement in Bank balances other than Cash and cash equivalents	(3.25)	31.06
Investment in associate	(1.23)	(9.07)
Investment in others	-	(17.65)
Interest received	4.60	4.83
Net cash used in investing activities (B)	(863.12)	(476.77)
Cash flow from financing activities		
Proceeds from exercise of employee stock options	15.29	18.95
Repayment of long - term borrowings	(148.28)	(178.18)
Proceeds from long - term borrowings	78.50	43.76
Proceeds from/ (Repayment of) short - term borrowings (net)	133.86	(396.73)
Proceeds from/ (Repayment of) supplier financing arrangements (net)	37.42	(15.53)
Payment of lease liabilities	(7.82)	(6.41)
Dividend paid	(64.78)	(43.14)
Interest paid	(79.64)	(90.68)
Proceeds from Government Grant	5.00	-
Net cash used in financing activities (C)	(30.45)	(667.96)
Net decrease in cash and cash equivalents (A+B+C)	(88.61)	(51.60)
Effect of exchange differences on cash and cash equivalents	0.40	1.83
Cash and cash equivalents at the beginning of the period	112.66	99.54
Cash and cash equivalents at the period end	24.45	49.77



Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Notes:

- 1 The above consolidated unaudited financial results of Laurus Labs Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 29, 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2026.
- 2 These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The consolidated financial results include the results of the following entities:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Sriam Labs Private Limited	India	Subsidiary	100%
Laurus Holdings Limited	UK	Subsidiary	100%
Laurus Generics Inc	USA	Step-down subsidiary	100%
Laurus Generics GmbH.L (Refer note 4c)	Germany	Step-down subsidiary	100%
Laurus Synthesis Private Limited	India	Subsidiary	100%
Laurus Generics SA (Pty) Ltd	South Africa	Subsidiary	100%
Laurus Bio Private Limited	India	Subsidiary	78.34%
Laurus Specialty Chemicals Private Limited (Refer note 4a)	India	Subsidiary	100%
ImmunoAdoptive Cell Therapy Private Limited	India	Associate	34.89%
Ethan Energy India Private Limited	India	Associate	26.00%
KRKA Pharma Private Limited (Refer note 4b)	India	Joint Venture	49.00%

- 4 a) The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations.
b) Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited ("KRKA"), Capital contribution of ₹ 49 Crores have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31, 2025 for 49% stake. The Company has accounted for the investment in KRKA as joint venture.
c) During the quarter, Laurus Generics GmbH has filed for Liquidation. The liquidation process is ongoing and remains subject to completion of the statutory one-year creditor objection period ending August 2027. The Net assets and results of the subsidiary are not material to the group.
- 5 The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 6 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company have filed the Scheme with the Hon'ble National Company Law Tribunal, Amaravati Bench at Amaravati, Andhra Pradesh, and accordingly the implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company are presented without giving effect to the said merger.
- 7 During the six months ended September 30, 2026, the Company allotted 455,636 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- 8 The Board of Directors, at their meeting held on October 29, 2026 approved for the payment of interim dividend of ₹ 1.00/- per equity share of ₹ 2/- each.

Place: Hyderabad
Date : October 29, 2026



By order of the Board
For Laurus Labs Limited

Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
LAURUS LABS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its associates and joint venture for the quarter and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Laurus Labs Limited, the Parent company
 - b. Laurus Bio Private Limited, India, Subsidiary
 - c. Sriam Labs Private Limited, India, Wholly Owned Subsidiary
 - d. Laurus Synthesis Private Limited, India, Wholly Owned Subsidiary
 - e. Laurus Holdings Limited, United Kingdom, Wholly Owned Subsidiary
 - f. Laurus Generics Inc., United States of America, (Subsidiary of (e) above)
 - g. Laurus Generics GmbH, Germany, (Wholly Owned Subsidiary of (e) above)
 - h. Laurus Generics SA (Pty) Limited, South Africa, Wholly Owned Subsidiary
 - i. Laurus Specialty Chemicals Private Limited, India, Wholly Owned Subsidiary
 - j. ImmunoAdoptive Cell Therapy Private Limited, India, Associate
 - k. Ethan Energy India Private Limited, India, Associate
 - l. KRKA Pharma Private Limited, India, Joint Venture



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of six subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of ₹ 735.27 crores as at September 30, 2026, total revenues of ₹ 146.35 crores and ₹ 323.49 crores for the quarter and six months ended September 30, 2026 respectively, total net loss after tax of ₹ 18.56 crores and ₹ 24.52 crores for the quarter and six months ended September 30, 2026 respectively and total comprehensive loss of ₹ 18.56 crores and ₹ 24.52 crores for the quarter and six months ended September 30, 2026 respectively and net cash outflows of ₹ 49.36 crores for the six months ended September 30, 2026, as considered in the Statement. The consolidated unaudited results also includes the Group's share of loss after tax of ₹ 0.76 Crores and ₹ 0.62 Crores for the quarter and six months ended September 30, 2026, as considered in the statement, in respect of one joint venture, whose interim financial information have not been reviewed by us. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results also includes the Group's share of loss after tax of ₹ 0.65 crores and ₹ 0.49 crores for the quarter and six months ended September 30, 2026 respectively and total comprehensive loss of ₹ 0.65 crores and ₹ 0.49 crores for the quarter and six months ended September 30, 2026 respectively, as considered in the Statement, in respect of an associate, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

C Manish Muralidhar

Partner

Membership No. 213649

UDIN: 26213649OEHMXW6902

Place: Hyderabad
Date: October 29, 2026

LAURUS LABS LIMITED
 (CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021

Corp. Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India.

Tel: +91 040 6659 4333 ; Fax : +91 040 6659 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2026

₹ in Crores

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations	2,014.11	1,757.16	1,566.60	3,771.27	2,999.35	6,089.07
	(b) Other income	24.72	20.07	28.45	44.79	49.97	77.43
	Total income	2,038.83	1,777.23	1,595.05	3,816.06	3,049.32	6,166.50
2	Expenses						
	(a) Cost of materials consumed	887.81	777.51	644.40	1,665.32	1,217.29	2,624.93
	(b) Purchase of traded goods	45.01	35.12	30.70	80.13	69.20	172.56
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(126.90)	(94.55)	(25.58)	(221.45)	(26.76)	(236.87)
	(d) Employee benefits expense	230.76	216.00	182.31	446.76	362.21	757.86
	(e) Other expenses	346.82	324.02	345.11	670.84	660.37	1,332.33
	(f) Depreciation and amortisation expense	97.69	95.76	95.59	193.45	189.16	378.64
	(g) Finance costs	38.02	35.20	33.68	73.22	77.57	142.96
	Total expenses	1,519.21	1,389.06	1,306.21	2,908.27	2,549.04	5,172.41
3	Profit before tax (1-2)	519.62	388.17	288.84	907.79	500.28	994.09
4	Tax expense						
	(a) Current tax	141.44	103.25	87.93	244.69	147.59	285.12
	(b) Deferred tax	(9.95)	(5.04)	(14.76)	(14.99)	(20.92)	(31.51)
	Total Tax expense	131.49	98.21	73.17	229.70	126.67	253.61
5	Net Profit after tax (3-4)	388.13	289.96	215.67	678.09	373.61	740.48
6	Other comprehensive income/(loss)						
	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) on defined benefit plans	(2.42)	(2.42)	(0.26)	(4.84)	(0.51)	3.88
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	0.61	0.61	0.07	1.22	0.13	(0.98)
	Total other comprehensive income/(loss), net of tax	(1.81)	(1.81)	(0.19)	(3.62)	(0.38)	2.90
7	Total comprehensive income (5+6)	386.32	288.15	215.48	674.47	373.23	743.38
8	Paid-up equity share capital (face value ₹ 2/- each)	108.06	108.05	107.96	108.06	107.96	107.97
9	Other equity						5,143.97
10	Earnings per equity share (face value ₹ 2/- each)						
	- Basic (₹)	7.18	5.37	3.99	12.55	6.92	13.72
	- Diluted (₹)	7.18	5.36	3.99	12.54	6.92	13.70
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

See accompanying notes to the financial results



Registered Office
Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
 Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
 Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Sl. No.	Particulars	As at September 30, 2026	As at March 31, 2026
		Unaudited	Audited
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	2,834.19	2,892.97
(b)	Right-of-use assets	140.53	131.60
(c)	Capital work-in- progress	974.81	569.42
(d)	Other Intangible assets	15.06	16.48
(e)	Financial assets		
(i)	Investments	890.94	890.94
(ii)	Other financial assets	37.92	36.68
(iii)	Loans	502.50	501.50
(f)	Deferred tax assets (net)	11.11	-
(g)	Other non-current assets	284.13	137.85
	Total non-current assets (1)	5,691.19	5,177.44
	Current assets		
(a)	Inventories	2,470.89	2,136.11
(b)	Financial assets		
(i)	Trade receivables	2,036.82	2,023.25
(ii)	Cash and cash equivalents	0.24	37.51
(iii)	Bank balances other than Cash and cash equivalents	0.59	0.31
(iv)	Loans	6.71	6.67
(v)	Other financial assets	4.59	3.89
(c)	Other current assets	186.69	154.85
	Total current assets (2)	4,706.53	4,362.59
	Total - assets (1+2)	10,397.72	9,540.03
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	108.06	107.97
(b)	Other equity	5,774.33	5,143.97
	Total equity (1)	5,882.39	5,251.94
	Liabilities		
	Non-current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	348.92	378.21
(ii)	Lease liabilities	88.76	73.80
(b)	Provisions	128.56	118.13
(c)	Deferred tax liability (net)	-	5.10
(d)	Other non-current liabilities	426.71	454.94
	Total non-current liabilities (2)	992.95	1,030.18
	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	1,737.06	1,620.54
(ii)	Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	38.50	45.34
	-total outstanding dues of creditors other than micro enterprises and small enterprises	1,264.79	1,151.93
(iii)	Lease liabilities	4.86	7.82
(iv)	Other financial liabilities	258.02	275.91
(b)	Other current liabilities	60.56	67.93
(c)	Provisions	40.12	35.42
(d)	Income tax liabilities (net)	118.47	53.02
	Total current liabilities (3)	3,522.38	3,257.91
	Total - equity and liabilities (1+2+3)	10,397.72	9,540.03


Registered Office
Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangli Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Standalone Statement of Cash Flows

₹ in Crores

Particulars	For the six months ended September 30, 2026	For the six months ended September 30, 2025
	Unaudited	Unaudited
Cash flow from operating activities		
Profit before tax	907.79	500.28
Adjustments for :		
Depreciation and amortisation	193.45	189.16
(Profit)/Loss on sale of property, plant and equipment (net)	0.42	1.49
Finance income	(27.59)	(24.97)
Interest expense	69.71	75.45
Share based payment expense	5.47	5.41
Net (gain)/loss on foreign exchange fluctuations (unrealised)	(8.72)	(10.92)
Allowance for expected credit loss and bad debts (net)	14.78	51.39
Operating profit before working capital changes	1,155.31	787.29
Movement in working capital:		
Increase in inventories	(334.77)	(74.19)
(Increase)/Decrease in trade receivables	(52.94)	103.13
Increase in financial and non-financial assets	(29.43)	(2.56)
Increase in trade payables	119.36	36.79
Increase/(Decrease) in financial, non-financial liabilities and provisions	(18.08)	211.32
Cash generated from operations	839.45	1,061.78
Income tax paid	(179.24)	(93.96)
Net cash generated from operating activities (A)	660.21	967.82
Cash flow from investing activities		
Purchase of property, plant and equipment, including intangible assets, and movement in capital work in progress, capital advances and capital creditors	(698.44)	(319.48)
Proceeds from sale of property, plant and equipment	0.86	2.47
Movement in Bank balances other than Cash and cash equivalents	(0.29)	0.01
Investment in associate	-	(9.07)
Investment in others	-	(17.65)
Investment in subsidiaries	-	(40.00)
Loan given to subsidiaries	133.00	(129.50)
Loan repaid by subsidiaries	(134.00)	132.00
Interest received	27.59	24.97
Net cash used in investing activities (B)	(671.28)	(356.25)
Cash flow from financing activities		
Proceeds from exercise of employee stock options	15.29	18.95
Repayment of long - term borrowings	(111.17)	(139.00)
Proceeds from long - term borrowings	64.50	43.76
Proceeds from/(Repayment of) Short - term borrowings (net)	117.98	(453.36)
Proceeds from/(Repayment of) supplier financing arrangements (net)	25.05	(5.00)
Payment of lease liabilities	(5.26)	(5.79)
Dividend paid	(64.78)	(43.14)
Interest paid	(67.81)	(78.04)
Net cash used in financing activities (C)	(26.20)	(661.62)
Net Decrease in cash and cash equivalents (A+B+C)	(37.27)	(50.05)
Cash and cash equivalents at the beginning of the period	37.51	50.36
Cash and cash equivalents at the period end	0.24	0.31


Registered Office
Laurus Labs Limited

 Laurus Enclave, Plot Office 01, E. Bonangi Village,
 Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

 Plot No. 103, Road No.1, Jubilee Hills,
 Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Notes:

- 1 The above standalone unaudited financial results of Laurus Labs Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 29, 2026. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2026.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 4 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Siam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company have filed the Scheme with the Hon'ble National Company Law Tribunal, Amaravati Bench at Amaravati, Andhra Pradesh, and accordingly the implementation of the Scheme is subject to the final approvals and sanctions of the applicable authorities. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the financial results of the Company are presented without giving effect to the said merger.
- 5 During the six months ended September 30, 2026, the Company allotted 455,636 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- 6 The Board of Directors, at their meeting held on October 29, 2026 approved for the payment of interim dividend of ₹ 1.00/- per equity share of ₹ 2/- each.

Place: Hyderabad
Date : October 29, 2026



By order of the Board
For Laurus Labs Limited



Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer

Registered Office
Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No.1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

C Manish Muralidhar
Partner

Membership No. 213649
UDIN: 26213649XXDSGS6742

Place: Hyderabad
Date: October 29, 2026